A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

April 18, 2025

Study Completion Date

May 2, 2025

Conditions
Atherosclerotic Cardiovascular Disease
Interventions
DRUG

Placebo

"0 mg (Placebo). Participants will receive three bottles, each containing 35 tablets with placebo tablets.~Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose."

DRUG

AZD0780

"Dose 1 Participants will receive three bottles, each containing 35 tablets:~* 1 bottle of dose a AZD0780 tablets~* 1 bottle of dose b AZD0780 tablets~* 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose."

Trial Locations (26)

12553

Research Site, New Windsor

19044

Research Site, Horsham

20854

Research Site, Potomac

29303

Research Site, Spartanburg

32127

Research Site, Port Orange

32216

Research Site, Jacksonville

33012

Research Site, Hialeah

33122

Research Site, Miami

33165

Research Site, Miami

33173

Research Site, Miami

33174

Research Site, Miami

33321

Research Site, Tamarac

33434

Research Site, Boca Raton

34474

Research Site, Ocala

45431

Research Site, Beavercreek

60621

Research Site, Chicago

75149

Research Site, Mesquite

75230

Research Site, Dallas

75462

Research Site, Paris

76054

Research Site, Hurst

78704

Research Site, Austin

79905

Research Site, El Paso

90301

Research Site, Inglewood

91325

Research Site, Northridge

91767

Research Site, Pomona

02740

Research Site, New Bedford

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Fortrea

INDUSTRY

lead

AstraZeneca

INDUSTRY